HMGB1 Redox During Sepsis

Wasan Abdulmahdi
Devika Patel
May Rabadi
Tala Azar
Edson Jules

See next page for additional authors

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs

Part of the Amino Acids, Peptides, and Proteins Commons

Recommended Citation

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact jogrady@nymc.edu.
**HMGB1 redox during sepsis**

Wasan Abdulmahdi, Devika Patel, May M. Rabadi, Tala Azar, Edson Jules, Mark Lipphardt, Rameen Hashemiyoon, Brian B. Ratliff

**A B S T R A C T**

During sepsis, the alarmin HMGB1 is released from tissues and promotes systemic inflammation that results in multi-organ damage, with the kidney particularly susceptible to injury. The severity of inflammation and pro-damage signaling mediated by HMGB1 appears to be dependent on the alarmin's redox state. Therefore, we examined HMGB1 redox in kidney cells during sepsis. Using intravitral microscopy, CellROX labeling of kidneys in live mice indicated increased ROS generation in the kidney perivascular endothelium and tubules during lipopolysaccharide (LPS)-induced sepsis. Subsequent CellROX and MitoSOX labeling of LPS-stressed endothelial and kidney proximal tubule cells demonstrated increased ROS generation in these cells as sepsis worsens. Consequently, HMGB1 oxidation increased in the cytoplasm of kidney cells during its translocation from the nucleus to the circulation, with the degree of oxidation dependent on the severity of sepsis, as measured in in vivo mouse samples using a thiol assay and mass spectrometry (LC-MS/MS). The greater the oxidation of HMGB1, the greater the ability of the alarmin to stimulate pro-inflammatory cyto-/chemokine release (measured by Luminex Multiplex) and alter mitochondrial ATP generation (Luminescent ATP Detection Assay). Administration of glutathione and thioredoxin inhibitors to cell cultures enhanced HMGB1 oxidation during lipopolysaccharide (LPS)-induced sepsis. Subsequent CellROX and MitoSOX labeling of LPS-stressed endothelial and kidney proximal tubule cells demonstrated increased ROS generation in these cells as sepsis worsens. Conversely, the glutathione and thioredoxin systems work to maintain the protein in its reduced state.

1. Introduction

Sepsis is a major cause of death in hospitalized patients [1]. During sepsis, enhanced oxidative stress and stimulation of pro-inflammatory cyto-/chemokines promote tissue damage, which leads to kidney and other organ failure [2–4]. During the early onset of endotoxemia, pathogen microbial elements referred to as pathogen-associated molecular patterns (PAMPs) (including lipopolysaccharide - LPS) activate immune, endothelial and epithelial cells by stimulating toll-like receptors (TLRs) [5–7]. Activation of TLRs induces the rapid release of early pro-damage signals, including damage-associated molecular patterns (DAMPs) that are referred to as alarmins, into the circulation [8,9]. Once released into the circulation, these alarmin molecules stimulate the release of pro-inflammatory factors and wide damage systemically.

A major alarmin that is released from tissues within the first 24 h of endotoxemia is High Mobility Group Box 1 protein (HMGB1). HMGB1 is typically found in the nucleus of a variety of cells (including immune, endothelial and epithelial cells) where it is bound to DNA. After activation of TLRs on these cells [8], acetylation of HMGB1 triggers its translocation from the nucleus to the circulation [10]. Once in the circulation, HMGB1 interacts with a variety of target cell receptors including RAGE, TLR2, and TLR4 [11–17] and stimulates release of pro-inflammatory cyto-/chemokines [14,15,17–20]. As sepsis worsens, the pro-damage effects of HMGB1 worsens causing progressive tissue and organ damage [21].

During sepsis, excessive ROS is generated by various cells and multiple sources, including enhanced activity of NAPDH oxidase and dehydrogenase/xanthine oxidase enzymes [22–29], altered mitochondrial bioenergetics [30], fatty acid oxidation (peroxisomal metabolism) and impaired peroxisomal catalase activity [31]. Enhanced levels of...
3. Results and discussion

3.1. ROS generation

We first examined total ROS levels in the circulation of animals 24 h after LPS-induced sepsis. In these experiments, two different doses of LPS were administered intraperitoneally to separate sets of animals, a low LPS dose (10 µg/kg) and a high LPS (1 mg/kg) dose. The low dose increased ROS in the circulation only slightly in animals, although the increase was not statistically significantly (Fig. 1a). In contrast, the high LPS dose resulted in a significant increase in circulating ROS within 24 h after LPS delivery.

Since the kidney is especially susceptible to oxidative damage, we examined ROS generation in kidneys during sepsis. To localize kidney ROS generation, we intraperitoneally perfused the membrane permeable ROS labeling dye CellRIOX into septic mice 24 h after LPS (1 mg/kg) delivery and imaged exposed kidneys in live animals using real-time intravital microscopy. CellRIOX reacts with oxidative molecules, such as superoxide and hydroxyl, which are generated from NADPH oxidase, xanthine oxidase and mitochondrial respiration. CellRIOX staining demonstrated enhanced ROS generation in the kidney perivascular endothelium and tubules (Fig. 1b) during sepsis.

Due to the potential of kidney endothelial and tubule cells to produce ROS, we further examined ROS generation in endothelial (HUVEC) and HK-2 cells during sepsis. We initially examined the time course of ROS generation in these cells. In experiments, cultured cells were separately treated with three different doses of LPS; a low (1 µg/ml), medium (10 µg/ml) or high (20 µg/ml) LPS dose to mimic mild-to-severe sepsis, respectively. All doses increased ROS in both endothelial and proximal tubule cells, although the highest dose promoted a drastically greater generation of ROS (Fig. 1c,e; Supplemental Fig. 1). In these experiments, cellular ROS was again detected in live cells by CellRIOX. Since the kidney is especially susceptible to oxidative damage and more specifically mitochondrial ROS generation was also significantly elevated within 24 h of treatment with LPS in endothelial and proximal tubule cells, with the higher LPS doses prompting greater mitochondrial ROS generation in both cell types (Fig. 1d,f; Supplemental Fig. 1).

3.2. HMGB1 redox

We have previously shown that during LPS-induced stress, HMGB1 undergoes nuclear-to-cytoplasmic translocation in kidney cells and is then released into the circulation [37]. Therefore, we next examined the redox state, and more specifically the thiol content of HMGB1, during the protein's LPS-induced translocation and release. In these experiments, HMGB1 thiol content was measured in HMGB1 isolated from nuclear and cytoplasmic kidney fractions and from the plasma after LPS administration. These experiments used whole kidney fractions and did not distinguish between specific cell type differences in HMGB1 redox (i.e. endothelial versus epithelial cells). When animals were treated with a low dose of LPS (10 µg/kg) to mimic mild sepsis, HMGB1 demonstrated increased oxidation in the cytoplasm and...
circulation, as indicated by decreased thiol content. However, the increase was statistically insignificant (Fig. 2a-c). Conversely, HMGB1 demonstrated significant oxidation in the cytoplasmic compartment and remained oxidized in the circulation during high LPS dose treatment (Fig. 2a-c). To confirm oxidation of HMGB1 in the cytoplasm of kidney cells, we also subjected these samples to mass spectrometry analysis. Liquid chromatography in tandem with mass spectrometry (LC-MS/MS) confirmed oxidation of HMGB1 in the cytoplasm during LPS-induced stress. LC-MS/MS identified the oxidation of cysteine residues at positions 23 and 45 (C23 and C45) and subsequent formation of a disulfide bond between these two residues during LPS treatment, with enhanced disulfide bond formation as LPS-induced stress was increased (Fig. 2d-f). The difference in HMGB1 thiol content during low versus high LPS-induced stress presumably indicates a heterogeneous mixture of HMGB1 whose cysteines are still in reduced thiol form along with cysteines that have formed a disulfide bond. This was similarly observed in experiments conducted by Veneau et al., in which supernatants of THP-1 monocytes treated with LPS contained both all-thiol and disulfide bonded HMGB1 [35].

Our results indicate HMGB1 becomes oxidized in the cytoplasm of kidney cells before its release into the circulation. This finding suggests increased intracellular generated ROS from sources such as NADPH oxidase and dysfunctional mitochondria oxidize HMGB1 in the cytoplasm during its nuclear-to-cytoplasmic translocation prior to release into the plasma. Furthermore, similar to the study by Veneau et al., utilizing monocytes, HMGB1 in the nucleus of kidney cells remains in reduced thiol form.

3.3. HMGB1 reduction by thioredoxin and glutathione

The thioredoxin and glutathione reduction pathways are two parallel, interdependent enzymatic systems present in all eukaryotic cells [29]. While both pathways are composed of multiple enzymes, including critical reductases, the thioredoxin and glutathione enzymes themselves are key enzymes in their respective systems [38]. Both systems play critical roles in the maintenance of intra-/extracellular redox balance [30] by maintaining proteins in their reduced state [29,39,40]. Thioredoxin and glutathione have both been shown to interact and reduce isolated purified HMGB1 [32,33]. Therefore, we questioned if these systems maintain reduction of HMGB1 during sepsis. We first examined total thioredoxin and glutathione activity in the cellular compartments of kidney cells and in the circulation 24 h after low and high LPS dose administration. Despite a negligible change in circulating thioredoxin levels 24 h after LPS administration, the change in intracellular and extracellular levels of thioredoxin and glutathione were dependent on the severity of endotoxin stress. Specifically, our results demonstrated thioredoxin activity was initially increased in the nucleus and cytoplasm during mild sepsis, but as sepsis became more severe, thioredoxin activity decreased in these compartments (Fig. 3a). In contrast, glutathione activity increased significantly in both the nucleus and circulation as LPS-induced sepsis worsened (Fig. 3a). Interestingly, cytoplasmic glutathione levels drastically declined as sepsis worsened, suggesting the simultaneous increase of circulating glutathione was a result of its enhanced release from the cytoplasm into the circulation.

We next examined the ability of these antioxidant systems to maintain reduced HMGB1 within kidney cells during LPS-induced stress. These experiments were conducted on HUVEC and HK-2 cell cultures. A relatively low dose of LPS was implemented in these experiments (10 µg/ml) as to not overwhelm the antioxidant capacity of the thioredoxin and glutathione systems. In endothelial cells, while inhibition of glutathione and thioredoxin had no effect on HMGB1 redox in the nucleus, conversely, inhibition of either antioxidant enhanced HMGB1 oxidation in the cytoplasm (Fig. 3b-e). In tubular epithelial cells, the thioredoxin inhibitor auranofin increased HMGB1 oxidation in the nucleus and cytoplasm, while the glutathione inhibitor L-BSO only had an influence on HMGB1 redox in the nucleus (Fig. 3d-e). These findings indicate glutathione and thioredoxin maintain HMGB1 in its reduced form in kidney cells during sepsis, with cell-type and cellular-compartment dependent differences in their specific effects on HMGB1 redox.

3.4. HMGB1 redox state impacts stimulation of cyto-/chemokine release and ATP generation

Once in the circulation, HMGB1 can stimulate the release of pro-inflammatory cyto-/chemokines from various cells and tissues [20,35,41–47]. However, the impact that the change in HMGB1 redox has on the protein’s ability to promote cyto-/chemokine release during sepsis remains unclear. Therefore, we examined the specific cyto-/chemokines that are systemically released in response to HMGB1 that is oxidized to different extents due to differences in sepsis severity. For these experiments, HMGB1 was captured from the circulation of mice 24 h after treatment with either low (10 µg/kg) or high (1 mg/kg) LPS dose. HMGB1 was also captured from the circulation of control animals. The purified HMGB1 was then intravenously administered to healthy mice. After 6 h, cyto-/chemokine levels in the circulation was measured by Luminex Multiplex. As HMGB1 became more oxidized, the protein’s ability to stimulate systemic release of pro-inflammatory cyto-/chemokines was enhanced, particularly regarding release of IL-1β, IL-17, TNFα, MIP-1α, MIP-1β, MIP-2, G-CSF and GM-CSF (Fig. 4a).

Sepsis is characterized by an increase in total cellular metabolism in order to provide the energy needed to sustain immune system activation [22]. However, the molecules that stimulate the hypermetabolic state are uncertain. When isolated mitochondria (purified from whole kidney homogenates) were treated with low and high oxidized HMGB1, mitochondrial ATP generation increased (Fig. 4b). As HMGB1 oxidation increased, its stimulatory effect on ATP generation was enhanced. This suggests HMGB1 and its oxidative state plays a role in stimulating a hypermetabolic state during sepsis.

4. Conclusions

During sepsis, oxidative stress increases the kidney, which leads to oxidation of HMGB1 during its release from kidney cells. Oxidation of HMGB1 enhances its pro-inflammatory signaling. However, glutathione and thioredoxin work to maintain HMGB1 in a reduce state in kidney cells.

Funding

Studies were supported by AHA grant 12SDG9080006, ASN grant

Fig. 3. Sepsis-induced oxidative stress leads to oxidation of HMGB1. HMGB1 thiol content in the (A) nuclear and (B) cytoplasmic compartments of kidney cells and in the (C) plasma 24 h after treatment with either low (10 µg/kg) or high (1 mg/kg) LPS dose. *p ≤ 0.05 vs. control; n = 5. (D-F) LC-MS/MS analysis was conducted on cytoplasmic fractions to confirm HMGB1 oxidation in the cytoplasm. (D) LC-MS/MS spectra trace of kidney cytoplasmic samples show two HMGB1 peptides with a retention time of 29.01 mins that are connected by a disulfide bond between C23 and C45 (peptide sequences are indicated in the figure). The disulfide bonded peptides appear as a peak at 477 m/z (identified as disulfide bond between C23 and C45 by MassMatrix software analysis). The absence of the thiol marker iodoacetamide and sulfonate marker dimedone further indicates these two cysteines are disulfide bonded. (E) Sample comparison of the elution traces (and subsequent area assignments) of disulfide bonded peptides with a peak at 477 m/z and a retention time of 29.01 mins. Samples compared included HMGB1 isolated from cytoplasmic fractions of mice whole kidneys 24 h after mice were treated with low and high LPS dose. (F) Quantification of the elution trace area assignments representative of the amount of HMGB1 C23-C45 disulfide bonded in each sample. Statistical significance is not given in panel F because multiple (n = 5) individual samples were pooled together and analyzed collectively for each of the three sample conditions.
Fig. 3. Glutathione and thioredoxin maintain HMGB1 in reduced form during sepsis. (A) Glutathione and thioredoxin activity in the nuclear and cytoplasmic compartments of fractionated whole kidneys and in the plasma 24 h after mice were treated with low (10 µg/kg) or high (1 mg/kg) LPS dose. Values in the graphs are represented by percent change relative to control. n = 4–5 (except thioredoxin plasma and cytoplasm treated with 10 µg/kg of LPS, which had an n = 3). Thiol content of HMGB1 localized in the (B) nucleus and (C) cytoplasm of HUVEC 24 h after treatment with LPS (10 µg/ml) and specific inhibitors of glutathione (L-BSO) or thioredoxin (Auranofin). *p ≤ 0.05 vs. control. n = 4–5. Thiol content of HMGB1 localized in the (D) nucleus and (E) cytoplasm of HK-2 cells 24 h after treatment with LPS (10 µg/ml) and L-BSO or Auranofin. *p ≤ 0.05 vs. control; †p ≤ 0.10 vs. control. n = 4–5.
010973-101, Westchester Community Foundation - Renal Clinical Fund, and a Seed Funding Grant award from the Biomedical and Health Sciences Research Council of the Touro College and University System (BBR).

Conflict of interest disclosures

All the authors declare no competing interests.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.redox.2017.08.001.

References
